- Canada's health ministry authorized the use of Pfizer Inc PFE and BioNTech SE's BNTX COVID-19 vaccine as a booster for children 5 - 11 years old at least six months after their initial two doses.-
- The 10 mcg dose was authorized, and this is the first COVID-19 vaccine authorized as a booster dose in this age group.
- The authorization for a booster shot was granted after a thorough, independent review of the vaccine, which provides "an option to restore their child's protection against COVID-19, especially those at high risk of severe illness," the health ministry wrote on Twitter.
- Also Read: Biden Administration To Stop Purchasing COVID-19 Solutions By End Of 2022.
- Moderna Inc's MRNA COVID-19 vaccine is authorized only as a primary series for children 6 - 11 years of age, using a 50 mcg dose, and for children six months to 5 years of age, using a 25 mcg dose.
- Booster doses of Moderna Spikevax (50 mcg) COVID-19 vaccine are authorized only for individuals 18 and older.
- In moderate to severely immunocompromised children, the Canadian authority recommends a primary series of three doses administered at least 4 to 8 weeks apart for both mRNA vaccines.
- Price Action: BNTX shares closed at $147.92, and PFE stock closed at $49.15 on Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in